Download Recently infected individuals: A priority for HIV prevention

From Prevention in Focus, Fall 2011
Recently infected individuals: A priority for HIV prevention
James Wilton
People living with HIV can potentially transmit HIV to others through unprotected sex at any time during their life.
However, emerging research suggests that a disproportionate number of HIV transmissions—perhaps more than
12
half—may originate from people during the first few months after they become infected with HIV. , In this article,
we explore why recently infected individuals are more likely to transmit HIV to others and how we can help prevent
these transmissions from occurring.
What’s happening in the body after HIV infection?
To understand why recently infected people are more likely to transmit HIV to others, we need to look at what’s
going on in the body after HIV infection occurs.
After someone becomes infected with HIV, the virus begins to replicate very quickly and the amount of virus in the
body and bodily fluids (such as the blood, semen, vaginal fluid and rectal fluid) rises rapidly. In some individuals, this
takes its toll on the body and can cause fever, fatigue, night sweats, headache, diarrhea, sore throat and/or a rash.
These symptoms generally appear about two weeks after infection occurs.3 Other individuals who become infected
notice no symptoms at all during this period.
A few weeks after infection, the body’s immune system begins to fight back against the virus. An important part of
this immune response includes the production of anti-HIV antibodies—small proteins made by certain immune cells,
which can destroy HIV and prevent HIV from multiplying. Once antibodies to HIV have been produced, HIV
replication begins to slow down and the amount of virus in the body (also known as the viral load) gradually
decreases. Unfortunately, antibodies cannot fully control HIV infection.
Antibodies are not produced immediately after infection. The amount of time it takes for the body’s immune system
to produce them varies from person to person. In most people, it is possible to detect HIV antibodies in their blood
within approximately 34 days of infection, although this can take up to three months in some individuals.4 The
presence of antibodies in the blood marks the end of the first stage of HIV infection—known as acute HIV
infection —and the beginning of the next stage, chronic HIV infection .
The amount of virus in the bodily fluids is highest during the acute HIV infection stage. After antibodies are
produced, the viral load slowly decreases but does not stabilize at a lower level until up to six months after
5 6 7 8 9 10
infection. , , , , ,
Why do people with recent HIV infection account for a disproportionate number of
transmissions?
Higher infectiousness
The elevated viral load of someone recently infected with HIV is the main biological reason that they are more likely
to transmit HIV to others at this time. The higher the viral load, the greater the risk is of transmitting HIV to others
through unprotected sex. Researchers estimate that the risk of transmitting HIV to another person from one act of
unprotected sex is 26 times higher during the first three months after infection than during the months and years
"10",11
that follow.
More high-risk behaviour
A high viral load alone is not enough to transmit HIV to another person; a recently infected individual also needs to
be engaging in activities that can lead to the transmission of HIV, such as unprotected sex. Unfortunately, a person
who has recently been infected with HIV is more likely to be engaging in high-risk behaviours than a person who has
12 13 14 15
been infected for a longer period of time. , , , There are two possible explanations for this. First, a recently
infected individual is more likely to be engaging in high-risk behaviours because this is what led to their HIV infection.
Second, many recently infected individuals are unaware of their HIV status and therefore may not realize the
importance of having safer sex.
Reducing the number of transmissions from recently infected individuals:
Challenges and solutions
Because recently infected individuals account for a large number of HIV transmissions, identifying these individuals
and helping them reduce their risk of passing HIV to others is critical to HIV prevention. Research shows that when
people become aware of their HIV infection and are provided with access to prevention and care services, most take
measures to reduce their risk of transmitting HIV to others."12"
There are two major challenges to identifying recently infected individuals:
1. the low levels of HIV testing in Canada; and
2. the limitations of certain HIV tests.
As a consequence, many people who have recently become infected are unaware of their infection, as are their
partners. Those who are recently infected may therefore continue to engage in high-risk behaviours until they are
diagnosed with HIV.
Your organization may be able to play a role in overcoming these challenges, identifying these individuals, and
reducing their risk of transmitting HIV to others.
Challenge: Low levels of HIV testing
It is estimated that 26% of people who are HIV-positive in Canada do not know that they are infected 16 and many
17 18
do not learn of their HIV status until they have been infected for several years. , The low levels of HIV testing in
Canada means that most recently infected people probably pass through the brief stage of HIV infection when their
viral load is elevated without getting tested for HIV.
People who have recently become infected may be unlikely to get tested for several reasons. Firstly, many may
believe that they are not at risk for HIV infection despite participating in behaviours that put them at risk. Secondly,
there are no definitive signs that someone has become infected with HIV. Only some people who have recently
become infected will experience symptoms and those symptoms are not specific to HIV infection. Therefore, many
people who experience symptoms may confuse them with those of another illness and not get tested. Furthermore,
for people who do believe that they are at risk of infection, there are several barriers that may prevent them from
getting an HIV test, including stigma and discrimination, fear of criminalization, and barriers to accessing testing and
other health services.
Solutions
Outreach and educational campaigns are needed to improve people’s awareness of their risk of infection and
of the symptoms associated with recent HIV infection. People need to be encouraged to get tested if they are
engaging in behaviours that put them at risk for HIV infection or have developed symptoms (such as fever,
fatigue, night sweats, headache, diarrhea, sore throat and/or a rash) after a high-risk exposure.
Frontline service providers need to increase awareness of the need for, and benefits of, HIV testing among
people who are at risk of infection. It is important that HIV-positive people learn about their HIV status as soon
as possible after infection, regardless of whether or not their viral load is still high, so that they can access
treatment and support services for people living with HIV and counselling on ways to prevent transmitting HIV.
Access to HIV testing, particularly for marginalized populations who are at risk of HIV infection, needs to be
improved. Frontline organizations may be able to play a role advocating for improved access.
Challenge: Limitations of HIV tests
The limitations of tests used to detect HIV infection is another major barrier to identifying recently infected
individuals.
Several types of HIV tests are available but for each type of test there is a brief period of time after infection during
which they are unable to detect infection in a person who is HIV-positive. The time period from when a person
becomes infected with HIV to when an HIV test can detect their infection, is known as the “window period.” During
the “window period,” an HIV test may find a recently infected person to be HIV-negative. The length of the “window
period” is different for each type of test and varies from person to person.19
The HIV tests most commonly used in Canada look for antibodies to HIV in the blood. These tests cannot detect HIV
infection in someone who has acute HIV infection because the body has not yet produced antibodies. The “window
period” for antibody tests varies because some people produce antibodies faster than others. For most people (up
to 95%), the window period of the antibody test is approximately one month, but for some individuals it may be as
long as three months.
This means that for people at high risk of HIV, testing can be done as early as one month after exposure using
standard antibody assays and rapid point-of-care tests. People who test positive will know for certain they are HIVpositive. Of those who test negative, 95% are indeed negative. Up to 5% of people who test negative at one month
could later test positive at three months. It is important to ensure that people who test negative at one month are
advised to return for repeat testing once the three-month window period is over.
Other HIV tests have been developed, which detect the virus itself—such as the HIV RNA or the p24 antigen tests.
These have shorter window periods (from seven to 14 days) than antibody tests and so can potentially detect HIV
infection during the acute phase.20 Unfortunately, access to these new testing technologies varies across Canada.
Another limitation of HIV tests is the time it takes for many of them to produce results. Most HIV tests do not
produce results immediately and require people to wait one to two weeks before getting the results. During this
time, people may continue to engage in high-risk behaviours and some people may never return to get their test
results.
Tests known as rapid or point-of-care (POC) tests can provide results on the same day that a test is performed.
Most rapid/POC tests can provide results within minutes. This ensures that a person receives their results. Rapid
tests that detect antibodies are available in some parts of Canada but rapid tests that can detect HIV RNA or the
p24 antigen do not yet exist.
Solutions
Frontline service organizations need to increase people’s awareness of the different “window periods” for each
type of HIV test, and emphasize that a negative result does not necessarily mean that a person is HIV-negative.
Messaging should emphasize that a person who has recently tested HIV-negative may be in the “window
period” and may be highly infectious. Knowledge of the “window period” and the increased risk of transmission
during this time is particularly important for people who base their decisions of whether or not to have
unprotected sex on knowledge of their HIV status or their partner’s.
People who test HIV-negative within the “window period” should be encouraged to refrain from high-risk
behaviours and return for another HIV test at an appropriate time. A second test is important to rule out the
“window period” as the reason for the test being negative. In Canada, we encourage people who test HIVnegative on an antibody test to test again at the end of the three-month “window period,” or sooner if
appropriate.
Organizations should learn if, and where, rapid antibody testing or RNA/p24 testing is available in their area. A
person who is suspected of being in the acute stage of HIV infection (for example, if they have recently had a
high-risk exposure or they have experienced flu-like symptoms after the exposure) should be referred to a site
where RNA or p24 testing is available. Service providers may need to advocate for improved access to rapid
antibody testing and RNA/p24 tests in their area.
Conclusion
The goal of HIV prevention is to reduce the number of HIV infections in the communities we serve. A large number
of HIV transmissions in your communities may be occurring from recently infected individuals, and therefore
represent an important priority for HIV prevention efforts. Although several challenges exist in identifying these
individuals and engaging them in prevention services, frontline organizations can play a key role in overcoming these
challenges and reducing HIV transmissions.
Hottest at the Start – A campaign by the Health initiative for Men (HiM) in BC to raise awareness on acute infection
and transmission and to encourage gay men who have had a recent potential exposure to HIV to get an ‘early’ HIV
test.
References
Miller WC, Rosenberg NE, Rutstein SE, Powers KA. Role of acute and early HIV infection in the sexual transmission of HIV. Current Opinion
in HIV and AIDS . 2010 Jul;5(4):277-82.
2.
Brenner BG, Roger M, Routy J et al. High rates of forward transmission events after acute/early HIV-1 infection. Journal of Infectious
Diseases . 2007 Apr 1;195(7):951-9.
3.
Lindbäck S, Thorstensson R, Karlsson AC et al. Diagnosis of primary HIV-1 infection and duration of follow-up after HIV exposure.
Karolinska Institute Primary HIV Infection Study Group. Swedish Institute for Infectious Disease Control/Karolinska Institute. AIDS . 2000
Oct 20;14(15):2333-9.
4.
Zetola NM, Pilcher CD. Diagnosis and management of acute HIV infection. Infectious Disease Clinics of North America . 2007
Mar;21(1):19-48.
5.
Morrison CS, Demers K, Kwok C et al. Plasma and cervical viral loads among Ugandan and Zimbabwean women during acute and early
HIV-1 infection. AIDS . 2010 Feb 20;24(4):573-82.
6.
Pilcher CD, Eron JJ, Galvin S et al. Acute HIV revisited: new opportunities for treatment and prevention. Journal of Clinical Investigation .
2004 Apr;113(7):937-45.
7.
Schacker TW, Hughes JP, Shea T et al. Biological and virologic characteristics of primary HIV infection. Annals of Internal Medicine . 1998
Apr 15;128(8):613-20.
8.
Richardson BA, Mbori-Ngacha D, Lavreys L et al. Comparison of human immunodeficiency virus type 1 viral loads in Kenyan women, men,
and infants during primary and early infection. Journal of Virology . 2003 Jun;77(12):7120-3.
9.
Pilcher CD, Joaki G, Hoffman IF et al. Amplified transmission of HIV-1: comparison of HIV-1 concentrations in semen and blood during
acute and chronic infection. AIDS . 2007 Aug 20;21(13):1723-30.
10. Wawer MJ, Gray RH, Sewankambo NK et al. Rates of HIV-1 transmission per coital act, by stage of HIV-1 infection, in Rakai, Uganda.
Journal of Infectious Diseases . 2005 May 1;191(9):1403-9.
11. Hollingsworth TD, Anderson RM, Fraser C. HIV-1 transmission, by stage of infection. Journal of Infectious Diseases . 2008 Sept
"10".
1;198(5):687-93.
12. Marks G, Crepaz N, Senterfitt JW, Janssen RS. Meta-analysis of high-risk sexual behavior in persons aware and unaware they are infected
with HIV in the United States: implications for HIV prevention programs. Journal of Acquired Immune Deficiency Syndromes . 2005 Aug
1;39(4):446-53.
13. Moore ZS, McCoy S, Kuruc J et al. Number of named partners and number of partners newly diagnosed with HIV infection identified by
persons with acute versus established HIV infection. Journal of Acquired Immune Deficiency Syndromes . 2009 Dec 1;52(4):509-13.
14. Marks G, Crepaz N, Janssen RS. Estimating sexual transmission of HIV from persons aware and unaware that they are infected with the
virus in the USA. AIDS . 2006 Jun 26;20(10):1447-50.
15. Colfax GN, Buchbinder SP, Cornelisse PGA et al. Sexual risk behaviors and implications for secondary HIV transmission during and after
HIV seroconversion. AIDS . 2002 Jul 26;16(11):1529-35.
16. Government of Canada Public Health Agency of Canada. HIV/AIDS Epi Updates—July 2010. [Cited 2011 May 12]. Available from:
"12".
www.phac-aspc.gc.ca/aids-sida/publication/epi/2010/2-eng.php
17. Althoff KN, Gange SJ, Klein MB et al. Late presentation for human immunodeficiency virus care in the United States and Canada. Clinical
Infectious Diseases . 2010 Jun 1;50(11):1512-20.
18. Plitt SS, Mihalicz D, Singh AE et al. Time to testing and accessing care among a population of newly diagnosed patients with HIV with a
high proportion of Canadian Aboriginals, 1998-2003. AIDS Patient Care and STDs . 2009 Feb;23(2):93-9.
19. Cohen MS, Gay CL, Busch MP, Hecht FM. The detection of acute HIV infection. Journal of Infectious Diseases . 2010 Oct 15;202 Suppl
2:S270-7.
20. Pilcher C, Christopoulos K, Golden M. Public health rationale for rapid nucleic acid or p24 antigen tests for HIV. Journal of Infectious
Diseases . 2010 April 15;201 Suppl 1:S7-15.
1.
About the author(s)
James Wilton is the Project Coordinator of the Biomedical Science of HIV Prevention Project at CATIE. James has an
undergraduate degree in Microbiology and Immunology from the University of British Columbia.
Produced By:
555 Richmond Street West, Suite 505, Box 1104
Toronto, Ontario M5V 3B1 Canada
Phone: 416.203.7122
Toll-free: 1.800.263.1638
Fax: 416.203.8284
www.catie.ca
Charitable registration number: 13225 8740 RR
Disclaimer
Decisions about particular medical treatments should always be made in consultation with a qualified medical
practitioner knowledgeable about HIV- and hepatitis C-related illness and the treatments in question.
CATIE provides information resources to help people living with HIV and/or hepatitis C who wish to manage their own
health care in partnership with their care providers. Information accessed through or published or provided by
CATIE, however, is not to be considered medical advice. We do not recommend or advocate particular treatments
and we urge users to consult as broad a range of sources as possible. We strongly urge users to consult with a
qualified medical practitioner prior to undertaking any decision, use or action of a medical nature.
CATIE endeavours to provide the most up-to-date and accurate information at the time of publication. However,
information changes and users are encouraged to ensure they have the most current information. Users relying
solely on this information do so entirely at their own risk. Neither CATIE nor any of its partners or funders, nor any
of their employees, directors, officers or volunteers may be held liable for damages of any kind that may result from
the use or misuse of any such information. Any opinions expressed herein or in any article or publication accessed
or published or provided by CATIE may not reflect the policies or opinions of CATIE or any partners or funders.
Information on safer drug use is presented as a public health service to help people make healthier choices to
reduce the spread of HIV, viral hepatitis and other infections. It is not intended to encourage or promote the use or
possession of illegal drugs.
Permission to Reproduce
This document is copyrighted. It may be reprinted and distributed in its entirety for non-commercial purposes
without prior permission, but permission must be obtained to edit its content. The following credit must appear on
any reprint: This information was provided by CATIE (the Canadian AIDS Treatment Information Exchange). For
more information, contact CATIE at 1.800.263.1638.
© CATIE
Production of this content has been made possible through a financial contribution from the Public Health Agency of
Canada.
Available online at:
http://www.catie.ca/en/pif/fall-2011/recently-infected-individuals-priority-hiv-prevention